On October 5–6, 2015, Moscow hosted the 7th conference «What’s going on in the pharma market?» with participation of more 350 leading pharma players. The discussion embraced major market trends in the recession setting, regulatory policy, investment attractiveness of the Russian pharma market as well as the problems of local manufacturers, and actions required to stimulate the Russian pharma industry.
A separate expert panel focused on creating a state monopoly on the immunobiological drug market. Recently, this issue has been broadly discussed by the professional community. Petrovax Pharm President Elena Arkhangelskaya took an active part in this discussion along with Nanolek President Vladimir Khristenko, Akrikhin Sales Director Rustem Muratov, and Synovate Comcon Healthcare Unit Director Oleg Feldman; the latter moderated the panel. The speakers discussed the risks of creating a state monopoly on the immunobiological drug market, investment attractiveness prospects for this segment as well as the vaccine market development in the new economic setting.
«As an immunobiological manufacturer, we are concerned about what is going on in the market, first of all, about the uncertainty introduced by the changes in the immunobiologicals purchasing and supply regulations,» emphasized Elena Arkhangelskaya.
«Immunobiology specifics is that this is a long process that requires substantial and continuous investment in manufacturing, primarily in quality. When the Federal Target Program „
When analyzing the investment attractiveness of the segment, Elena Arkhangelskaya remarked:
«We as a Russian immunobiological developer and manufacturer that has for a long time operated on the market, and has a